omeprazole and erythromycin
omeprazole has been researched along with erythromycin in 30 studies
Research
Studies (30)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (33.33) | 18.2507 |
2000's | 10 (33.33) | 29.6817 |
2010's | 9 (30.00) | 24.3611 |
2020's | 1 (3.33) | 2.80 |
Authors
Authors | Studies |
---|---|
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Pratim Roy, P; Roy, K | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
Baron, JH; Gummett, PA; Hegarty, BT; Logan, RP; Misiewicz, JJ; Walker, MM | 1 |
Bell, GD; Bolton, G; Brooks, S; Burridge, SM; Gant, PW; Harrison, G; Powell, KU; Prosser, S; Purser, K; Spencer, G | 1 |
Cederbrant, G; Kahlmeter, G; Kamme, C; Schalén, C | 1 |
Graham, SG; Krivoruk, Y; Tateishi, T; Wood, AJ | 1 |
Majka, J; Piotrowski, J; Slomiany, A; Slomiany, BL | 1 |
Estrada, R; Garcia, F; Laine, L; Stein, C; Trujillo, M | 1 |
Lambert, JR; Midolo, PD; Turnidge, JD | 1 |
Ishizaki, T; Zhao, XJ | 1 |
Campa, M; Favini, P; Malizia, T; Marchetti, F; Pizzarelli, G; Senesi, S; Tejada, M | 1 |
Busch, N; Handt, S; Heintz, B; Kierdorf, H; Marschall, H; Mertens, PR; Schönfelder, T; Sieberth, H | 1 |
Amat, C; Ancelin-Malbreil, E; Becquart, JP; Faulques, B; Michault, A; Picot, S; Sapin, G; Simac, C | 1 |
Fuhr, U; Kober, S; Mutschler, E; Spahn-Langguth, H; Zaigler, M | 1 |
Horikoshi, T; Kawamura, O; Kusano, M; Mori, M; Sekiguchi, T; Shimoyama, Y | 1 |
Bulko, TV; Dmitriev, AV; Filimonov, DA; Gilep, AA; Koroleva, PI; Kuzikov, AV; Makhova, AA; Masamrekh, RA; Rikova, SM; Shich, EV; Shumyantseva, VV; Zaviyalova, MG | 1 |
Reviews
1 review(s) available for omeprazole and erythromycin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Trials
4 trial(s) available for omeprazole and erythromycin
Article | Year |
---|---|
Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Bismuth; Circadian Rhythm; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Erythromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Stomach Ulcer | 1992 |
Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test.
Topics: Adult; Anti-Ulcer Agents; Breath Tests; Carbon Radioisotopes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; Humans; Male; Mixed Function Oxygenases; Omeprazole; Reference Values | 1995 |
Prospective evaluation of the macrolide antibiotic dirithromycin for the treatment of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Combinations; Erythromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Macrolides; Male; Metronidazole; Middle Aged; Omeprazole; Pilot Projects; Prospective Studies; Urea | 1996 |
Oral erythromycin accelerates impaired gastrointestinal motility after endoscopic mucosal resection.
Topics: Adenoma; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Erythromycin; Fasting; Follow-Up Studies; Gastric Mucosa; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Male; Middle Aged; Omeprazole; Postoperative Period; Stomach; Stomach Neoplasms; Treatment Outcome | 2007 |
Other Studies
25 other study(ies) available for omeprazole and erythromycin
Article | Year |
---|---|
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
Clarithromycin and omeprazole for Helicobacter pylori.
Topics: Clarithromycin; Erythromycin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 1992 |
Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori.
Topics: Amoxicillin; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Erythromycin; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Metronidazole; Microbial Sensitivity Tests; Omeprazole | 1994 |
Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Interactions; Erythromycin; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Penicillins; Sucralfate; Tetracycline | 1995 |
Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Synergism; Enzyme Inhibitors; Erythromycin; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors | 1997 |
Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Topics: Anti-Infective Agents; Antimalarials; Chromatography; Cytochrome P-450 Enzyme System; Doxycycline; Drug Interactions; Erythromycin; Humans; Hydroxylation; Ketoconazole; Microsomes, Liver; Nifedipine; Omeprazole; Primaquine; Quinine; Tetracycline; Troleandomycin | 1997 |
Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Synergism; Erythromycin; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Organometallic Compounds; Peptic Ulcer; Proton Pump Inhibitors; Roxithromycin | 1998 |
Long-term extracorporeal bilirubin elimination: A case report on cascade resin plasmaperfusion.
Topics: Acute Kidney Injury; Bile Acids and Salts; Charcoal; Chemical and Drug Induced Liver Injury; Cholestasis; Disseminated Intravascular Coagulation; Doxycycline; Epilepsy, Generalized; Erythromycin; Extracorporeal Circulation; Fatal Outcome; Hematoma, Subdural; Hepatic Encephalopathy; Humans; Hyperbilirubinemia; Liver Failure; Omeprazole; Pneumonia; Ranitidine; Resins, Plant; Shock, Septic; Thrombophlebitis | 1998 |
[Antibiotic resistance of Helicobacter pylori in Reunion Island: therapeutic consequences].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Ciprofloxacin; Clarithromycin; Confidence Intervals; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Random Amplified Polymorphic DNA Technique; Reunion; Stomach Ulcer; Tetracycline; Treatment Failure | 2002 |
Rate-limiting biotransformation of triamterene is mediated by CYP1A2.
Topics: Caffeine; Chromatography, High Pressure Liquid; Coumarins; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Humans; Hydroxylation; Ketoconazole; Kinetics; Microsomes, Liver; Omeprazole; Quinidine; Substrate Specificity; Sulfuric Acid Esters; Theophylline; Triamterene | 2005 |
[Modeling of drug-drug interactions between omeprazole and erythromycin with cytochrome P450 3A4 in vitro assay].
Topics: Anti-Bacterial Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Omeprazole; Proton Pump Inhibitors | 2020 |